secwatch.observer — SEC 8-K summary
======================================

Issuer:     Centessa Pharmaceuticals plc (CNTA)
CIK:        0001847903
Form:       8-K
Filed at:   2026-06-24T12:56:30+00:00
Accession:  0001193125-26-280337
Event type: m_and_a
Sentiment:  neutral
Materiality: 1.00
Item codes: 1.02, 2.01, 3.01, 3.03, 5.01, 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Centessa acquired by Eli Lilly for $38/sh plus up to $9/sh CVR
--------------------------------------------------------------

- Acquisition closed June 24, 2026; Centessa became wholly owned subsidiary of Lilly.
- Shareholders received $38.00 cash per share plus one CVR worth up to $9.00 on milestones.
- All outstanding equity awards cashed out based on $38.00 consideration; CVRs issued.
- Centessa terminated its Oxford Finance loan facility and Leerink ATM sales agreement.
- CEO, board, and other officers resigned; Christopher Stokes and Kristina Wright appointed directors.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1847903/000119312526280337/0001193125-26-280337-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1847903/000119312526280337/d150381d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-280337

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer